Best Cardiac and Vascular Disorders Companies in China
The 118 best Cardiac and Vascular Disorders companies in China in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Innovent Bio.
Tracking the best-funded Cardiac and Vascular Disorders companies in China, this directory covers 118 ventures and $2.6B in total disclosed equity, ranked by funding size and recent momentum. No unicorns yet, but the spread tells you something: Innovent Bio sits at $535M, Jixing at $127M, and Beijing X-Magtech Technologies at $29M, while earlier-stage names like Pulnovo Medical ($15M) and Pulsecare Medical Technology ($14M) are still actively raising. That gap between the top earner and the field isn't unusual for a sector still consolidating around proven device and therapy platforms.
What's worth watching is where the investor attention is clustering. Qiming Venture Partners, Hillhouse, and Lilly Asia Ventures are all in this mix, which tells me the smart money sees durable deal flow here, not a one-cycle bet. Coverage across the 118 companies is rising, and I'd flag cardiovascular hospital infrastructure and age-related cardiac risk as the themes pulling the most active diligence right now. So if you're mapping China's cardiac and vascular space, the funding concentration is real, the investor roster is serious, and the early-stage pipeline is thick enough to keep this sector moving through the rest of the year.
Ranked: Best Cardiac and Vascular Disorders companies in China
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Innovent Bio Developer of antibody therapeutics for multiple diseases | $535M | 46 mo ago | Public | 5,144 | Michael Yu Founder & CEO | Node.jsAnimate.cssVue.js+5 | — | 1 partnership |
| 2 | Lepu Medical Technology Interventional medical devices | $316M | 70 mo ago | Public | 10,652 | Pu Zhongjie Chairman & CEO | Cart FunctionalityPHPTengine+6 | — | — |
| 3 | Hasten Biopharma Developer of therapeutics for cardiovascular and metabolism fields | $315M | 38 mo ago | Series D | 700 | — | — | — | 1 award |
| 4 | LianBio Developer of therapeutics for cardiorenal and oncology diseases | $313M | 62 mo ago | Public | 163 | Bing Li CEO | Webflowanime.jsGSAP+10 | — | — |
| 5 | MicroPort CardioFlow Medtech Corporation Developer of smart medical devices for patients with heart valve diseases | $132M | 74 mo ago | Public | 200 | — | PHPWindows ServerMicrosoft ASP.NET+4 | 280 patents Percutaneous coronary intervention devices: balloon catheters, stent delivery systems, and control handles. | — |
| 6 | JIXING Developer of therapeutics for cardiovascular and ophthalmic conditions | $127M | 29 mo ago | Series D | — | Sandy Mou CEO | — | 20 patents Data storage media, brush manufacturing, ECG-based data security, sensor hubs, olefin polymerization catalysts. | — |
| 7 | Shanghai New Pulse Medical Technology Developer of an artifical heart valve and catheter implantation system | $114M | 62 mo ago | Series C | 268 | — | — | — | — |
| 8 | Peijia Medical Technologies Developer of medical devices for the treatment of cardiac and cerebrovascular diseases | $110M | 79 mo ago | Public | 1,006 | — | Animate.cssNginxSwiper+3 | — | — |
| 9 | Argo Biopharma Developer of oligonucleotide therapeutics for various diseases | $104M | 31 mo ago | Series A | — | Shiwei Xia Co-Founder | — | — | — |
| 10 | JJET R&D company focused on producing and supplying of medical devices | $103M | 46 mo ago | Series B | 321 | — | — | — | — |
| 11 | China Resources Bio-Pharmaceutic Developer of protein and antibody drugs to treat multiple diseases | $89M | 41 mo ago | Series B | 400 | — | — | — | — |
| 12 | Lifetech Scientific Corporation Interventional medical devices to treat cardiovascular and peripheral vascular diseases. | $66M | 164 mo ago | Public | 1,391 | — | Windows ServerAnimate.cssMicrosoft ASP.NET+3 | 5 patents Cardiac left atrial appendage occlusion devices and degradable iron alloy support structures | — |
| 13 | Insight Lifetech Developer of ultrathin pressure microcatheter for coronary stenosis. | $43M | 65 mo ago | Public | 522 | Liang Song Co-Founder | PHPTengineSwiper+2 | 21 patents Intravascular microcatheter devices and real-time ultrasound imaging/pressure analytics | 1 launch |
| 14 | Venus MedTech Transcatheter aortic valves | $37M | 97 mo ago | Public | 1,006 | Eric Zi Founder & CEO | PHPWindows ServerUIKit+6 | 354 patents Patents concentrated in health & consumer products | — |
| 15 | BEIJING X-MAGTECH TECHNOLOGIES Developer of non-invasive magnetic resonance imaging equipment 64Funding top 32%Market top 39%Talent bottom 45%Global bottom 36% All 4 signals ▾Fundingtop 32% Markettop 39% Talentbottom 45% Globalbottom 36% Funding: Raised $28.7M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) Market: 150 employees (top 24% of HealthTech) rank vs industry peers · Fliar Intelligence Index 64/100 | $29M | 23 mo ago | Series A | 150 | Bin Cai Founder & CEO | — | — | — |
| 16 | Imarx Therapeutics Developing and commercialising therapeutics for vascular disorders such as stroke | $27M | 225 mo ago | Acqui-Hired | — | Evan unger ex-CEO | — | — | — |
| 17 | NeuroTronik Cardiac autonomic nerve stimulation to treat acute heart failure | $23M | 110 mo ago | Deadpooled | — | Fred McCoy CEO | — | — | — |
| 18 | Shanghai Baixin'an Biotechnology Developer of coronary stent system | $16M | 79 mo ago | Public | 58 | — | — | — | — |
| 19 | Kossel Medtech Developer of cardiovascular medical devices | $16M | 29 mo ago | Series B | — | Navis Feng Co-Founder | WordPressMySQLPHP+16 | 6 patents Patents concentrated in health & consumer products | — |
| 20 | Pulnovo Medical Developer of a medical device for the treatment of pulmonary hypertension 62Moat top 25%Patents top 31%Innovation top 33%Funding top 38% All 9 signals ▾Moattop 25% Patentstop 31% Innovationtop 33% Fundingtop 38% Markettop 39% Growthtop 48% Talentbottom 49% Globalbottom 43% Newsbottom 34% Moat: Editorial + unicorn rating 7/10 · IP moat: 38 patents Patents: 38 patents matched (strict assignee match) · 27 filings since 2022 vs 10 in 2017-21 rank vs industry peers · Fliar Intelligence Index 62/100 | $15M | 15 mo ago | Series C | 100 | Jessie Lian CEO | — | 38 patents Catheter-based radiofrequency ablation of the pulmonary artery for heart‑failure therapy | 1 partnership |
| 21 | magAssist Developer of extracorporeal circulation assisting device | $15M | 56 mo ago | Series C | — | Polin Hsu Founder | — | 100 patents Design and integration of catheter pump systems for ventricular assist and fluid management | 1 award |
| 22 | Brattea Developer of a medical device for the treatment of hypertension | $15M | 26 mo ago | Series D | 19 | Hongguang Cao Founder | — | — | — |
| 23 | Shenqi Medical Developer of a medical device for cardiovascular surgeries | $14M | 69 mo ago | Series C | — | Dai Zhihao Founder | — | — | — |
| 24 | Kejun Pharmaceutical Developer of therapeutics for the treatment of cardiovascular and cerebrovascular diseases | $14M | 28 mo ago | Series B | — | Ho Kung- yan Founder & CEO | — | — | — |
| 25 | Pulsecare Medical Technology Developer of medical device solutions for heart and vascular care 22Funding top 44%Talent bottom 49%Market bottom 37%Global bottom 29% All 4 signals ▾Fundingtop 44% Talentbottom 49% Marketbottom 37% Globalbottom 29% Funding: Raised $14.0M across 1 rounds · 1 rounds over 2 yrs (0.5/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 22/100 | $14M | 7 mo ago | Series A | — | Javen Tan CEO | — | — | — |
| 26 | Huamai Tyco Developer of aortic stent system | $14M | 83 mo ago | Series B | 283 | Jian Zhou Founder & CEO | — | — | — |
| 27 | GenEditBio Provider of gene editing-based solutions for genetic diseases | $10M | 20 mo ago | Seed | — | Zheng Zongli Co-Founder | Microsoft ASP.NETTengineModernizr+2 | 26 patents Therapeutic CRISPR gene editing delivery via engineered proteins and lipid nanoparticles | — |
| 28 | Nanochap Bio-medical devices developer 69Talent top 35%Market top 39%Funding top 42%Global bottom 36% All 4 signals ▾Talenttop 35% Markettop 39% Fundingtop 42% Globalbottom 36% Talent: Analyst team rating 4/5 · 2 named leaders on record Market: 100 employees (top 25% of High Tech) rank vs industry peers · Fliar Intelligence Index 69/100 | $4M | 1 mo ago | Series B | 100 | Jiawei Yang Co-Founder & CEO | — | — | 1 job opening |
| 29 | Vulnerable Plaque Diagnostics Provider of magnetic angiography products | $2M | 190 mo ago | Funding Raised | 20 | — | — | — | — |
| 30 | 37mhealth Personal blood pressure management product and platform | $2M | 126 mo ago | Deadpooled | — | Wanhui Dai Founder | — | — | — |
| 31 | Guangdong Pulse Medical Technology Developer and manufacturer of cardiovascular medical devices | $1M | 45 mo ago | Series C | 15 | — | — | — | — |
| 32 | BioThera Solutions Developer of antibody drugs to treat multiple diseases | $149K | 84 mo ago | Public | 1,189 | — | — | — | — |
| 33 | Zeraph Contact free smart thermometer | $100K | 120 mo ago | Seed | 3 | Eddie Cheung Co-Founder | — | — | — |
Top 12 Cardiac and Vascular Disorders companies in China
#1
Series B · Hangzhou, Zhejiang · founded 2014 · 100 employees$3.8Mraised▾
Nanochap is a bio-medical device developer. Some of its devices include neural stimulator, blood pressure measurement, portable pain relief management. The company has developed the NanoHug, blood pressure measuring device, uses the electronic blood pressure measurement technology. The device contains a sensor for measuring diastolic blood pressure, systolic blood pressure, heart rate, and the pulse image of the human body.
- May 2026Series B$43.9M
- Dec 2016Series A$3.8M
#2
Series A · Shenzhen, Guangdong Province · founded 2021$14Mraised▾
Developer of medical device solutions for heart and vascular care. The products and platforms uses technologies such as pulsed electric fields and ultrasound to provide treatments for various cardiovascular conditions.
- Nov 2025Series A$14M
- Aug 2024Series A—
#3
Series C · Wuxi, Jiangsu · founded 2013 · 100 employees$15.5Mraised▾
Developer of a medical device for the treatment of pulmonary hypertension. The device PADN multipolar synchronous pulmonary artery radiofrequency ablation catheter transmits the high-frequency current for ablation of the pulmonary sympathetic nerve.
- Mar 2025Series C$100M
- Nov 2022Series A—
- Aug 2021Series A$15.5M
#4
Series A · Haidian, Beijing · founded 2020 · 150 employees$28.7Mraised▾
Developer of non-invasive magnetic resonance imaging equipment. The company offers a liquid-free helium magnetocardiography that detects the weak magnetic field for large-scale cardiovascular functional imaging.
- Jul 2024Series A$13.8M
- Jun 2022Series A$15M
#5
Public · Suzhou, Jiangsu · founded 2011 · 5144 employees$535Mraised▾
Developer of antibody therapeutics for multiple diseases. It offers monoclonal and bispecific antibodies to treat several cancers such as non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, colorectal cancer, and lung cancer. Also, has antibody binding to TNF-α preventing it from activating TNF receptors, and will be used to treat Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn’s disease, and other autoimmune diseases.
- Aug 2022Post IPO$307.9M
- Oct 2019Post IPO$299.8M
- Apr 2018Series E$150M
- Nov 2016Series D$260M
#6
Series D · Shanghai, Shanghai · founded 2019$127Mraised▾
Developer of therapeutics for cardiovascular and ophthalmic conditions. The lead candidate include Aficamten is a novel investigational small molecule cardiac myosin inhibitor that targets the underlying hypercontractility in HCML. Other product pipeline includes NZ100 and LNZ101 best-in-class treatment options with potential for all-day near vision improvement.
- Jan 2024Series D$127M
#7
Series D · Hefei, Anhui · founded 2020 · 700 employees$315Mraised▾
Developer of therapeutics for cardiovascular and metabolism fields. The company develops a product pipeline in the field of chronic disease and age-related disease management. The company's product line includes Anidin for Cardiovascular disease and Basexin for Metabolism conditions.
- Apr 2023Series D$315M
#8
Seed · Hong Kong, Hong Kong · founded 2021$10Mraised▾
Provider of gene editing-based solutions for genetic diseases. The company develops precision gene-editing technology and develop a pipeline of programmable gene therapy products.
- Sep 2024Seed—
- Apr 2024Seed$10M
#9
Series A · Shanghai, Shanghai · founded 2021$103.8Mraised▾
Developer of oligonucleotide therapeutics for various diseases. The company specializes in siRNA drug discovery and development, utilizing siRNA platform technology and RADS to offer a pipeline of therapeutics for cardiovascular, rare diseases, CNS diseases, viral hepatitis, metabolic diseases, and more.
- Nov 2023Series A$41M
- Mar 2022Seed$62.8M
#10
Public · Shanghai, Shanghai · founded 1999 · 163 employees$313Mraised▾
Developer of therapeutics for cardiorenal and oncology diseases. The company is involved in the development of its candidate Infigratinib (BGJ398) which is orally administered FGFR1-3 tyrosine kinase inhibitor and can be used in FGFR-driven diseases, like cholangiocarcinoma and urothelial carcinoma. Other lead candidate is BBP-398 which is an allosteric SHP2 inhibitor for wild-type SHP2, used in the treatment of tumors having SHP2 activity and Mavacamten is used in the treatment of cardiac contractility.
- Apr 2021Unattributed$3M
- Oct 2020Unattributed$310M
#11
Series B · Shenzhen, Guangdong Province · founded 2016 · 400 employees$88.5Mraised▾
Developer of protein and antibody drugs to treat multiple diseases. It focuses on the research and development of antibodies, vaccines, and recombinant proteins, for the treatment of tumors, cardiovascular and cerebrovascular diseases, allergic diseases, etc.
- Jan 2023Series B$88.5M
#12
Public · Beijing, Beijing · founded 1999 · 10652 employees$315.8Mraised▾
Lepu Medical Technology is engaged in the development, manufacturing, and marketing of cardiac therapy related products. The company offers products under eight main categories: Interventional cardiology (Stent, Balloon, Catheter, and Guidewire); Structural heart disease (occlusion devices, prosthetic heart valves); Heart rhythm (Electrophysiology catheter, Implantable pacemaker, Pacemaker lead); cardiac in vitro diagnosis products (analyzer, cardiac biomarkers test cassette, Thrombelastography hemostasis analyzer), Anesthetic products, Interventional angiography system, Surgical stapler, and Neurological intervention products. The company has 7 wholly-owned and joint stock subsidiary companies.
- Aug 2020Post IPO$185.8M
- Apr 2020Post IPO—
- Jul 2019Post IPO$130M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Cardiac and Vascular Disorders coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.